Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A Canadian Working Group report on fecal microbial therapy: microbial ecosystems therapeutics.

Allen-Vercoe E, Reid G, Viner N, Gloor GB, Hota S, Kim P, Lee C, O'Doherty K, Vanner SJ, Weese JS, Petrof EO.

Can J Gastroenterol. 2012 Jul;26(7):457-62. Review.

2.

Frequency of Th17 CD20+ cells in the peripheral blood of rheumatoid arthritis patients is higher compared to healthy subjects.

Eggleton P, Bremer E, Tarr JM, de Bruyn M, Helfrich W, Kendall A, Haigh RC, Viner NJ, Winyard PG.

Arthritis Res Ther. 2011;13(6):R208. doi: 10.1186/ar3541. Epub 2011 Dec 15.

3.

Measurement and meaning of markers of reactive species of oxygen, nitrogen and sulfur in healthy human subjects and patients with inflammatory joint disease.

Winyard PG, Ryan B, Eggleton P, Nissim A, Taylor E, Lo Faro ML, Burkholz T, Szabó-Taylor KE, Fox B, Viner N, Haigh RC, Benjamin N, Jones AM, Whiteman M.

Biochem Soc Trans. 2011 Oct;39(5):1226-32. doi: 10.1042/BST0391226. Review.

PMID:
21936794
4.

Inducible hydrogen sulfide synthesis in chondrocytes and mesenchymal progenitor cells: is H2S a novel cytoprotective mediator in the inflamed joint?

Fox B, Schantz JT, Haigh R, Wood ME, Moore PK, Viner N, Spencer JP, Winyard PG, Whiteman M.

J Cell Mol Med. 2012 Apr;16(4):896-910. doi: 10.1111/j.1582-4934.2011.01357.x.

5.

Electrocardiographic assessment for therapeutic proteins--scientific discussion.

Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK.

Am Heart J. 2010 Oct;160(4):627-34. doi: 10.1016/j.ahj.2010.07.001. Review.

PMID:
20934555
6.

Extracellular calreticulin is present in the joints of patients with rheumatoid arthritis and inhibits FasL (CD95L)-mediated apoptosis of T cells.

Tarr JM, Winyard PG, Ryan B, Harries LW, Haigh R, Viner N, Eggleton P.

Arthritis Rheum. 2010 Oct;62(10):2919-29. doi: 10.1002/art.27602.

7.

Changes in apoptotic gene expression in lymphocytes from rheumatoid arthritis and systemic lupus erythematosus patients compared with healthy lymphocytes.

Eggleton P, Harries LW, Alberigo G, Wordsworth P, Viner N, Haigh R, Donnelly S, Jones HW, Chikanza IC, O'Conner TW, Thomson AE, Winyard PG.

J Clin Immunol. 2010 Sep;30(5):649-58. doi: 10.1007/s10875-010-9429-y. Epub 2010 Jun 9.

PMID:
20532967
8.

Towards multidisciplinary teamworking in musculoskeletal care: evolution of a service.

Ainsworth R, Conboy V, Norman J, Viner N.

Musculoskeletal Care. 2004;2(2):113-9. No abstract available.

PMID:
17041975
9.

Changes in rheumatology out-patient workload over 12 years in the South West of England.

Kirwan JR, Averns H, Creamer P, Davies M, Hickling P, Hutton C, Jacoby R, Kyle V, Laversuch C, Palferman T, Tobias J, Viner N, Woolf A, Yates D.

Rheumatology (Oxford). 2003 Jan;42(1):175-9. No abstract available.

PMID:
12509633
10.

The effects of deimination of myelin basic protein on structures formed by its interaction with phosphoinositide-containing lipid monolayers.

Ishiyama N, Bates IR, Hill CM, Wood DD, Matharu P, Viner NJ, Moscarello MA, Harauz G.

J Struct Biol. 2001 Oct;136(1):30-45.

PMID:
11858705
11.

Influence of a dominant cryptic epitope on autoimmune T cell tolerance.

Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC.

Nat Immunol. 2002 Feb;3(2):175-81. Epub 2002 Jan 14.

PMID:
11812995
12.

Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP.

Manoury B, Mazzeo D, Fugger L, Viner N, Ponsford M, Streeter H, Mazza G, Wraith DC, Watts C.

Nat Immunol. 2002 Feb;3(2):169-74. Epub 2002 Jan 14.

PMID:
11812994
13.

T cell recognition of the dominant I-A(k)-restricted hen egg lysozyme epitope: critical role for asparagine deamidation.

McAdam SN, Fleckenstein B, Rasmussen IB, Schmid DG, Sandlie I, Bogen B, Viner NJ, Sollid LM.

J Exp Med. 2001 Jun 4;193(11):1239-46.

14.

Nicotine replacement combined with a novel compound (ProBAN) for smoking cessation: a pilot study.

Leigh R, Viner NM, Cox G, Balon JW, Wilson DM, O'Shaughnessy D, Walker C, Brosky G, Sears MR.

Can Respir J. 2001 Jan-Feb;8(1):21-6.

15.

Characterization of a recombinant murine 18.5-kDa myelin basic protein.

Bates IR, Matharu P, Ishiyama N, Rochon D, Wood DD, Polverini E, Moscarello MA, Viner NJ, Harauz G.

Protein Expr Purif. 2000 Nov;20(2):285-99.

PMID:
11049752
16.

Enhanced co-stimulatory ability of synovial fluid accessory cells in rheumatoid arthritis.

Robertson SE, Young SP, Viner NJ, Bacon PA.

Br J Rheumatol. 1997 Apr;36(4):413-9.

PMID:
9159532
17.

Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules.

Nelson CA, Vidavsky I, Viner NJ, Gross ML, Unanue ER.

Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):628-33.

18.

Bridgeport Hospital autologous blood donation experience from 1992 to 1996.

Bernstein LH, Coles M, Viner N.

Yale J Biol Med. 1995 Sep-Dec;68(5-6):207-13.

19.

TCR-mediated adhesion of T cell hybridomas to planar bilayers containing purified MHC class II/peptide complexes and receptor shedding during detachment.

Dustin ML, Miller JM, Ranganath S, Vignali DA, Viner NJ, Nelson CA, Unanue ER.

J Immunol. 1996 Sep 1;157(5):2014-21.

PMID:
8757322
20.

A negatively charged anchor residue promotes high affinity binding to the MHC class II molecule I-Ak.

Nelson CA, Viner NJ, Young SP, Petzold SJ, Unanue ER.

J Immunol. 1996 Jul 15;157(2):755-62.

PMID:
8752926
21.

Appreciating the complexity of MHC class II peptide binding: lysozyme peptide and I-Ak.

Nelson CA, Viner NJ, Unanue ER.

Immunol Rev. 1996 Jun;151:81-105. Review. No abstract available.

PMID:
8872486
23.

Amino acid residues on the I-Ak alpha-chain required for the binding and stability of two antigenic peptides.

Nelson CA, Viner N, Young S, Petzold S, Benoist C, Mathis D, Unanue ER.

J Immunol. 1996 Jan 1;156(1):176-82.

PMID:
8598459
24.

Role of antigen presenting cells in rheumatoid arthritis.

Viner NJ.

Br Med Bull. 1995 Apr;51(2):359-67. Review.

PMID:
7552069
26.

Cross-sectional analysis of the differences between patients with systemic lupus erythematosus in England, Brazil and Sweden.

Johnson AE, Cavalcanti FS, Gordon C, Nived O, Palmer RG, Sturfelt G, Viner NJ, Bacon PA.

Lupus. 1994 Dec;3(6):501-6.

PMID:
7704008
27.

The progressive differentiation of primed T cells is associated with an increasing susceptibility to apoptosis.

Salmon M, Pilling D, Borthwick NJ, Viner N, Janossy G, Bacon PA, Akbar AN.

Eur J Immunol. 1994 Apr;24(4):892-9.

PMID:
8149960
28.
29.

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, Symmons DP, Viner N, Zoma A.

Q J Med. 1993 Jul;86(7):447-58.

PMID:
8210301
30.

Synovial fluid antigen-presenting cell function in rheumatoid arthritis.

Viner NJ, Gaston JS, Bacon PA.

Clin Exp Immunol. 1993 May;92(2):251-5.

31.

A case of dementia praecox treated by intraspinal injections of horse serum. 1933.

Viner N.

CMAJ. 1992 Sep 15;147(6):903-5. No abstract available.

32.

Isolation of Yersinia-specific T cell clones from the synovial membrane and synovial fluid of a patient with reactive arthritis.

Viner NJ, Bailey LC, Life PF, Bacon PA, Gaston JS.

Arthritis Rheum. 1991 Sep;34(9):1151-7.

PMID:
1718288
33.

Comment on the article by Pope et al.

Gaston JS, Life PF, Viner NJ, Bacon PA.

Arthritis Rheum. 1990 Oct;33(10):1596-8. No abstract available.

PMID:
2222544
34.

Medically significant concentrations of prostate-specific antigen in serum assessed.

Bernstein LH, Rudolph RA, Pinto MM, Viner N, Zuckerman H.

Clin Chem. 1990 Mar;36(3):515-8. Erratum in: Clin Chem 1993 May;39(5):896.

35.
36.

Calcium and phytochrome control of leaf unrolling in dark-grown barley seedlings.

Viner N, Whitelam G, Smith H.

Planta. 1988 Aug;175(2):209-13. doi: 10.1007/BF00392429.

PMID:
24221714
37.

Ureteroiliac vein fistula associated with a polyethylene indwelling ureteral stent.

Teuton ME, Viner NA, Zuckerman HL, Butler DL.

J Urol. 1987 May;137(5):975-6. No abstract available.

PMID:
3573202
38.

Acquired cystic disease of the kidney.

Viner NJ, MacIver AG, Mackenzie JC.

Br Med J (Clin Res Ed). 1987 Jan 10;294(6564):121-2. No abstract available.

39.

Leukoplakia associated with renal tuberculosis in the chemotherapeutic era.

Byrd RB, Viner NA, Omell GH, Trunk G.

Br J Urol. 1976 Oct;48(5):377-81.

PMID:
990686
40.

Extramammary Paget's disease in the scrotal and inguinal areas.

Hagan KW, Braren V, Viner NA, Page DL, Rhamy R.

J Urol. 1975 Jul;114(1):154-6. No abstract available.

PMID:
167199
41.

Bilateral nephrectomy: an analysis of 100 consecutive cases.

Viner NA, Rawl JC, Braren V, Rhamy RK.

J Urol. 1975 Mar;113(3):291-4. No abstract available.

PMID:
1117493
42.

Anaphylaxis manifested by hypotension alone.

Viner NA, Rhamy RK.

J Urol. 1975 Jan;113(1):108-10.

PMID:
1113380
43.

Prolonged renal failure following allotransplantation of cadaver kidney.

Viner NA, Staab EV, Ackermann JR.

South Med J. 1972 Apr;65(4):429-32. No abstract available.

PMID:
4555009
44.

Psychoanalysis.

VINER N.

Can Med Assoc J. 1951 Aug;65(2):108-12. No abstract available.

45.

Intensive vitamin treatment in some neuritides and some psychoses.

VINER N.

Can Med Assoc J. 1950 Feb;62(2):162-4. No abstract available.

46.

A modern approach to psychoanalysis.

VINER N.

Can Med Assoc J. 1948 Jul;59(1):36-42. No abstract available.

47.

Treatment in mental disease; especially the psychoneuroses.

VINER N.

Can Med Assoc J. 1946 Aug;55(2):101-5. No abstract available.

PMID:
20992743
48.

TREATMENT IN MENTAL DISEASE.

Viner N.

Can Med Assoc J. 1946 Aug;55(2):101-5. No abstract available.

49.

Methyl Bromide Poisoning: A New Industrial Hazard.

Viner N.

Can Med Assoc J. 1945 Jul;53(1):43-5. No abstract available.

50.

A CASE OF ENCEPHALITIS EPIDEMICA (LETHARGICA) TREATED BY SULPHANILAMIDE.

Viner N.

Can Med Assoc J. 1939 Jun;40(6):586. No abstract available.

Supplemental Content

Support Center